Reply

Sirs,

In regard to Dr. James' comments on our paper, we reported that patients with JRA have low levels of testosterone and dehydroepiandrosterone sulphate. Dr. James suggested that Aaron *et al.* published data strongly suggesting that the sex ratios of siblings of pro-bands with pauci- and polyarticular JRA are highly significantly different, with the paucis having an excess of sisters and the polys an excess of brothers. In our study, looking at the ratio of sisters and brothers in the patients that we evaluated, this theory could be debated. We evaluated ten polyarticular patients, of which one had four sisters, one had two sisters, two had one sister only, one had one sister and one brother, one was an only child, and four had one brother only. In the pauciarticular group we evaluated nine patients, of which five had one sister only, three were only children, and one had one brother. This did confirm that the pauciarticulars had an excess of sisters and the polyarticulars had more brothers; however, the dominant sibling type was female for both the polyarticular and pauciarticular groups. This would also suggest that polyarticular and pauciarticular JRA are not different with respect to their endocrinological antecedents. We thank Dr. James for his interesting comments and for the opportunity to address his intriguing theories.

T.L. MOORE, *MD, Professor of Internal Medicine and Pediatrics, Director, Division of Rheumatology, St. Louis University Health Sciences Center and Cardinal Glennon Children's Hospital, St. Louis, Missouri*

M.J.C. HENDRIX, *PhD, Professor and Head, Department of Anatomy and Cell Biology, Associate Director of Basic Research and Deputy Director, The Iowa Cancer Center, University of Iowa, Iowa City, Iowa*

Z. KHALKHALI-ELLIS, *PhD, Assistant Research Scientist, Department of Anatomy and Cell Biology, University of Iowa.*

Treatment of recurrent oro-genital ulceration with low doses of thalidomide

Sir,

Thalidomide in a dosage of 100 mg/day is an effective treatment for severe aphthous stomatitis but it is not without some risk (1). Some recent studies confirm that thalidomide in a dosage of 200 mg/day is an effective treatment for aphthous ulceration in patients with HIV infection (2), and that 100 mg/d is as effective as 300 mg/d for oral and genital ulcers (OGU) in Behçet's syndrome (3). Previous studies (4) have suggested that thalidomide was as effective at the dosage of 50 mg/d for aphthous ulceration and that the duration of treatment might be a major factor in the significant risk of polyneuropathy. In order to assess the dosage of thalidomide with the best efficacy/toxicity ratio, we performed a prospective study from 1993 to 1996.

The study was monocentric with an open design. The aim of the study was to define the lowest dosage of thalidomide required for complete clearing of all OGU after an initial dosage of 50 mg/day for one month. The inclusion period was from 1993 to 1996. The patients who participated gave their written informed consent. Precautions were taken to prevent pregnancy; all women of childbearing age were given pregnancy tests every month and used a reliable method of contraception.

The diagnosis of OGU, made by three of the physicians who participated in the study, was based on the clinical appearance of the lesions. Seventeen patients with OGU (mean age 43 yrs.; sex ratio M/F: 12/5) were included. The diagnosis was: recurrent oral ulcerations (8 pts.); oro-genital ulcerations (3 pts.); Behçet's syndrome (4 pts.); and recurrent OGU associated with leukemia (2 pts.). All patients had failed to respond to any other treatment (prednisone, colchicine, dapsone) and had serious (food intake impeded) or severe (only liquid intake) functional impairment.

The initial dosage of thalidomide was 50 mg/d (1 tablet) for all patients for one month; if the patient's status improved, the dosage was reduced to one tablet every other day for one month, then one tablet twice a week for the following months. Electrophysiologic tests were performed at the start of the study and every 6 months thereafter, using the methodology recommended by Gardner (5). A clinical neurological evaluation was carried out monthly.

Out of the 17 patients, 10 entered remission within the first month and 7 improved. Six of these entered remission after 2 months, and the last one after 4 months. Remission was prolonged on a 200 mg dosage administered over one week in 12/17 patients: out of 10 patients who tried a 150 mg dosage administered over one week only 4 relapsed, and out of the 6 patients who tried a 100 mg dosage administered over one week only one relapsed. The mean time of treatment was 22 months (5-54). The side effects were drowsiness (6 pts.), weight increase (2 pts.), mood disturbances (2 pts.), dry mouth (2 pts.) and hypotension (2 pts.). Electrophysiologic tests showed a decrease of sensory nerve action potential in 6 patients after a mean treatment time of 9 months. Treatment was withdrawn from only 3 patients because of paresthesia (2 pts.) and areflexia (1 pt). There was no difference in efficacy and toxicity of the treatment for Behçet's disease, leukemia or idiopathic OGU. All patients who tried to stop the drug (5 pts.) relapsed in a mean time of 7 weeks.

Our study shows that thalidomide is effective in the treatment of OGU at the low dose of 50 mg/d and that 1 tablet every 2 or 3 days was effective in maintaining remission in more than 60% of the patients. Mild electophysiologic abnormalities were frequent (6/17), but we never observed severe polyneuropathy. We conclude that in the treatment of OGU with thalidomide, a low dosage of 50 mg/d is effective in most cases, provided that the patient is carefully followed up to assure the early detection of peripheral neuropathy.

B. DE WAZIÈRES, *MD, PhD*

H. GIL, *MD*

D.A. VUITTON, *MD, PhD, Professor*

J.L. DUPOND, *MD, Professor*

Service de Médecine Interne, CHU Jean Minjoz, 25030 Besançon Cedex, France.

Please address correspondence to: Dr. B. de Wazières, Service de Médecine Interne, CHU Jean Minjoz, 25030 Besançon Cedex, France.

References

1. REVUZ J, GUILLAUME JC, JANIER M *et al.*: Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. *Arch Dermatol* 1990; 126: 923-7.
2. JACOBSON JM, GREENSPAN JS, SPRIKLER J *et al.*: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. *N Engl J Med* 1997; 336: 1487-93.
3. HAMURYUDAN V, MAT C, SAIP S *et al.*: Thalidomide in the treatment of the mucocutaneous lesions of the Behçet's syndrome. *Ann Intern Med* 1998; 128: 443-50.
4. DENMAN AM, GRAHAM E, HOWE L, DENMAN EJ, LIGHTMAN S: Low dose thalidomide treatment of Behçet's syndrome. *In:* WECHSLER B and GODEAU P (Eds.): *Behçet's Disease. Proceedings of the 6th International Conference on Behçet's Disease*. Amsterdam, Excerpta Medica 1993: 649-53.
5. GARDNER-MEDWIN JM, SMITH NJ, POWELL RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in condition such as Behçet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. *Ann Rheum Dis* 1994; 53: 828-32.